Cancer Prevention
Health
Pharmaceutical

Insys Therapeutics

$0.96
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.1018 (-9.60%) Today
+$0.0018 (0.19%) After Hours

Why Robinhood?

You can buy or sell INSY and other stocks, options, ETFs, and crypto commission-free!

About

INSYS Therapeutics, Inc. operates as a pharmaceutical company, which develops and commercializes supportive care products. It focuses on utilizing commercial pharmaceutical products that include Subsys, a proprietary sublingual fentanyl spray for BTCP in opioid-tolerant adult patients; and Syndros, a proprietary orally administered liquid formulation of dronabinol for the treatment of CINV and anorexia associated with weight loss in patients with AIDS. Read More The company was founded by John N. Kapoor on June 15, 1990 and is headquartered in Chandler, AZ.

Employees
226
Headquarters
Chandler, Arizona
Founded
1990
Market Cap
78.98M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
861.98K
High Today
$1.03
Low Today
$0.95
Open Price
$1.03
Volume
621.04K
52 Week High
$11.65
52 Week Low
$0.82

Collections

Cancer Prevention
Health
Pharmaceutical
Biotechnology
Therapy
Technology
US
North America

News

Seeking AlphaMay 16

Why Insys Therapeutics Is Unlikely To Survive

It has not been a pleasant week for Insys Therapeutics (INSY), as it has announced poor first-quarter 2019 results, along with a news release providing a liquidity update in which it is stated that there is substantial doubt about the company's ability to continue as a going concern.

2,316
Wall Street JournalMay 13

Opioid Trouble Weighs on Insys as Short Sellers Cash In

Short sellers are cashing in as the country’s opioid crisis begins claiming corporate casualties. Insys Therapeutics Inc. said Friday it could be headed to bankruptcy, short on cash and overloaded with legal costs from opioid addiction lawsuits and the racketeering convictions of co-founder John Kapoor and other former company executives. The......

2,079
CNBCMay 13

Drugmaker Insys shares tank after saying opioid lawsuits may force it into bankruptcy

A box of the Fentanyl-based drug Subsys, made by Insys Therapeutics Inc, is seen in an undated photograph provided by the U.S. Attorney's Office for the Southern District of Alabama.

2,950

Earnings

-$0.61
-$0.46
-$0.30
-$0.15
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.21 per share
Actual
-$0.55 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.